Key indicators: single-crystal X-ray study; T = 293 K; mean (C-C) = 0.009 Å; R factor = 0.035; wR factor = 0.094; data-to-parameter ratio = 24.2.
In the title compound, [ZnBr 2 (C 11 H 12 N 2 O 2 ) 2 ], the Zn(II) ion is coordinated by two Br atoms and two O atoms from two 4hydroxyantipyrine molecules via the carbonyl O atoms, which act as monodentate ligands, giving rise to a distorted tetrahedral geometry. The values of the bond angles at the Zn atom are in the range 99.4 (1) to 113.2 (1) . The presence of O-HÁ Á ÁO and O-HÁ Á ÁBr intramolecular hydrogen bonds can explain the difference between the two Zn-O [1.961 (3)/ 2.015 (3) Å ] and the two Zn-Br [2.350 (1)/2.378 (1) Å ] bond lengths. The crystal structure is governed by C-HÁ Á ÁO, C-HÁ Á ÁBr and Zn-BrÁ Á ÁCg(-ring) interactions.
Related literature
For related literature, see: Bekaert et al. (2003 Bekaert et al. ( , 2007 ; Filiz et al. (2008) ; Lemoine et al. (2007) ; Matzke et al. (2000) ; Melov et al., (1998) ; Panneerselvam et al. (1996) ; Tougu et al. (2008) .
Experimental
Crystal data [ZnBr 2 (C 11 Table 1 Hydrogen-bond geometry (Å , ). Table 2 Zn-BrÁ Á ÁCg(-ring) interaction. (2) 3.646 6.76 132.21 (4) Symmetry code: (i) 1 þ y, 1 À x, À 1 4 þ z. Cg1 is the centroid of atoms Cl/N2/N3/C4/C5. Data collection: CAD-4 EXPRESS (Enraf-Nonius, 1994); cell refinement: CAD-4 EXPRESS; data reduction: XCAD4 (Harms & Wocadlo, 1995) ; program(s) used to solve structure: SIR92 (Altomare et al., 1994); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEPIII (Burnett & Johnson, 1996) and ORTEP-3 for Windows (Farrugia, 1997) ; software used to prepare material for publication: WinGX (Farrugia, 1999) .
Dibromidobis(4-hydroxy-1,5-dimethyl-2-phenyl-3-pyrazolone)zinc(II) P. Lemoine, B. Viossat, J. D. Brion and A. Bekaert
Comment
Metals like Zn are expected to be involved in neurodegenerative diseases such as Alzheimer or Parkinson leading to neurofibrillary tangles degeneration and tau protein accumulation (Filiz et al.,2008; Tougu et al.,2008) . These amyloi¨d plaques in the cortical brain are the sign of cerebral aging and associated with a neuronic a high level of metals. Much work (Melov et al., 1998) is now devoted to theses diseases since no real drug is available up to date. As researchers postulate that soft chelating drugs could interfere with free metal accumulation and neuronal collapsus, our idea was that phenazone (antipyrine), a well known antipyretic brain available drug, could become a soft chelating molecule upon hydroxylation in the 4-hydroxy derivative. For this reason and our knowledge in metal amide complexes, (Bekaert et al., 2007; Lemoine et al., 2007) we have prepared a new cristalline complex including Zn and 4-hydroxy-1,5-dimethyl-2-phenyl-3-pyrazolone (4-hydroxyantipyrine)
which is of considerable interest as a antipyrine primary metabolite and which is the object of many biological studies the latter years, by example in the evaluation of the influence of diabete mellitus on antipyrine metabolism (Matzke et al., 2000) .
The hydroxyamide structure which is close to lactamide let us to test it as a metal pinch. Following our work concerning lactamide and zinc(II) complex (Bekaert et al., 2003) , we now report a new zinc complex with 4-hydroxyantipyrine.
The title compound contains one monomeric tetrahedral zinc complex, [Zn(C 22 H 24 N 4 O 4 )Br 2 ]. The Zn atom is surrounded by two monodentate 4-hydroxyantipyrine ligands via the carbonyl O atom O4 (or O24) in the sp 2 lone-pair direction and two Br ligands (Fig. 1) . The complex exhibits a distorted tetrahedral geometry around the zincII atom. The degree of deviation from an ideal tetrahedron is appreciable with the angles around Zn atom ranging from 99.4 (1) to 113.2 (1)°.
The Zn-O and Zn-Br distances in the coordination polyhedron are 1.961 (3)/2.015 (3) Å and 2.351 (1)/2.379 (1)Å, respectively, in good agreement with those found in similar Zn II tetrahedral coordination (Bekaert et al., 2003) . The difference between the two Zn-O (or the two Zn-Br) bond lengths can be explained by the presence of the O5-H5···O24 (or O25-H25···Br1) intramolecular hydrogen bond (Table 1) which causes the stretching of the Zn-O24 (or Zn-Br1) bond. Each hydroxyantipyrine ligand consists of a pyrazole P1 (Cl/N2-N3/C4-C5) [or P3 (C2l/N22-N23/C24-C25)] and a phenyl ring P2 (C8-C13) [or P4 (C28-C33)] which are planar with maximum deviation of 0.017 (3) Å for N2 (first ligand) and 0.021 (3) Å for N23 (second ligand). The dihedral angles are 65.2 (2)° between P1 and P2 and 81.6 (2)° for P3 and P4, these values are significantly different from those reported in 4-hydroxyantipyrine [42.5 (1)°] (Panneerselvam et al.,1996) .
The crystal packing is governed by weak C-H···O and Zn-Br···Cg1( centroid of the P1 plane) interactions (Tables1 and 2).
Experimental
The title compound, dibromido-bis[4-hydroxyantipyrine]zinc(II), was prepared by mixing 1.02 g (5 mmole) of 4-hydroxyantipyrine dissolved in hot acetic acid (10 ml, 353 K) and 10 ml of a solution of ZnBr2 (0.496 g, 2 mmole) in boiling acetic acid. Upon slow cooling, crystal suitable for X-ray diffraction were recovered. supplementary materials sup-2 Refinement All H atoms were positioned geometrically and treated as riding on their parent atoms with distances C-H = 0.96 Å (CH 3 ) and U iso (H) = 1.5 times U eq (C) or 0.93 Å (aromatic) with U iso (H) = 1.2 times U eq (C) and O-H= 0.82Å with U iso (H) = 1.5 times U eq (O). Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating Rfactors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq Zn1 0.74076 (5) 0.20414 (5) 
